Aberrant regulation of the cell cycle is a typical feature of all forms of cancer. In head and neck squamous cell carcinoma (HNSCC), it is often associated with the overexpression of cyclin D1 (CCND1). However, it remains unclear how CCND1 expression changes between tumor and normal tissues and whether human papillomavirus (HPV) affects differential CCND1 expression. Here, we evaluated the expression of D-type cyclins in a cohort of 94 HNSCC patients of which 82 were subjected to whole genome expression profiling of primary tumors and paired normal mucosa. Comparative analysis of paired samples showed that CCND1 was upregulated in 18% of HNSCC tumors. Counterintuitively, CCND1 was downregulated in 23% of carcinomas, more frequently in HPV-positive samples. There was no correlation between the change in D-type cyclin expression and patient survival. Intriguingly, among the tumors with downregulated CCND1, one-third showed an increase in cyclin D2 (CCND2) expression. On the other hand, one-third of tumors with upregulated CCND1 showed a decrease in CCND2. Collectively, we have shown that CCND1 was frequently downregulated in HNSCC tumors. Furthermore, regardless of the HPV status, our data suggested that a change in CCND1 expression was alleviated by a compensatory change in CCND2 expression.

Department of Informatics and Chemistry Faculty of Chemical Technology University of Chemistry and Technology 160 00 Prague Czech Republic

Department of Otorhinolaryngology 3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Department of Otorhinolaryngology Head and Neck Surgery 1st Faculty of Medicine Charles University Faculty Hospital Motol 150 06 Prague Czech Republic

Department of Pathology and Molecular Medicine Charles University 2nd Faculty of Medicine and Faculty Hospital Motol 150 06 Prague Czech Republic

Institute of Anatomy 1st Faculty of Medicine Charles University 128 00 Prague Czech Republic

Institute of Microbiology of the Czech Academy of Sciences 142 00 Prague Czech Republic

Laboratory of Genomics and Bioinformatics Institute of Molecular Genetics of the Czech Academy of Sciences 142 20 Prague Czech Republic

Zobrazit více v PubMed

Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010;127:2893–2917. doi: 10.1002/ijc.25516. PubMed DOI

Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. PubMed DOI

Kalavrezos N., Bhandari R. Current trends and future perspectives in the surgical management of oral cancer. Oral Oncol. 2010;46:429–432. doi: 10.1016/j.oraloncology.2010.03.007. PubMed DOI

Fung C., Grandis J.R. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin. Emerg. Drugs. 2010;15:355–373. doi: 10.1517/14728214.2010.497754. PubMed DOI PMC

Hashibe M., Brennan P., Chuang S.C., Boccia S., Castellsague X., Chen C., Curado M.P., Dal Maso L., Daudt A.W., Fabianova E., et al. Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol. Biomark. Prev. 2009;18:541–550. PubMed PMC

Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316. doi: 10.1016/j.oraloncology.2008.06.002. PubMed DOI

Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., et al. Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. J. Natl. Cancer Inst. 2000;92:709–720. PubMed

Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol. 2014;26:13–21. doi: 10.1016/j.semcancer.2013.11.002. PubMed DOI

Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systemic review. Cancer Epidemiol. Biomark. Prev. 2005;14:467–475. doi: 10.1158/1055-9965.EPI-04-0551. PubMed DOI

Psyrri A., Rampias T., Vermorken J.B. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 2014;25:2101–2115. doi: 10.1093/annonc/mdu265. PubMed DOI

Dayyani F., Etzel C.J., Liu M., Ho C.-H., Lippman S.M., Tsao A.S. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) Head Neck Oncol. 2010;2:15. doi: 10.1186/1758-3284-2-15. PubMed DOI PMC

Ragin C.C.R., Modugno F., Gollin S.M. The epidemiology and risk factors of head and neck cancer: A focus on human papillomavirus. J. Dent. Res. 2007;86:104–114. doi: 10.1177/154405910708600202. PubMed DOI

Leemans C.R., Braakhuis B.J.M., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer. 2011;11:9–22. doi: 10.1038/nrc2982. PubMed DOI

Leemans C.R., Snijders P.J.F., Brakenhoff R.H. The molecular landscape of head and neck cancer. Nat. Rev. Cancer. 2018;18:269–282. doi: 10.1038/nrc.2018.11. PubMed DOI

Lawrence M.S., Sougnez C., Lichtenstein L., Cibulskis K., Lander E., Gabriel S.B., Getz G., Ally A., Balasundaram M., Birol I., et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582. PubMed PMC

Chen W.S., Bindra R.S., Mo A., Hayman T., Husain Z., Contessa J.N., Gaffney S.G., Townsend J.P., Yu J.B. CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Front. Oncol. 2018;8:95. doi: 10.3389/fonc.2018.00095. PubMed DOI PMC

Dok R., Nuyts S. HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers. 2016;8:41. doi: 10.3390/cancers8040041. PubMed DOI PMC

Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer. 2011;11:558–572. doi: 10.1038/nrc3090. PubMed DOI

Deshpande A., Sicinski P., Hinds P.W. Cyclins and cdks in development and cancer: A perspective. Oncogene. 2005;24:2909–2915. doi: 10.1038/sj.onc.1208618. PubMed DOI

VanArsdale T., Boshoff C., Arndt K.T., Abraham R.T. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin. Cancer Res. 2015;21:2905–2910. doi: 10.1158/1078-0432.CCR-14-0816. PubMed DOI

Bova R.J., Quinn D.I., Nankervis J.S., Cole I.E., Sheridan B.F., Jensen M.J., Morgan G.J., Hughes C.J., Sutherland R.L. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res. 1999;5:2810–2819. PubMed

Hermida-Prado F., Menéndez S., Albornoz-Afanasiev P., Granda-Diaz R., Álvarez-Teijeiro S., Villaronga M., Allonca E., Alonso-Durán L., León X., Alemany L., et al. Distinctive Expression and Amplification of Genes at 11q13 in Relation to HPV Status with Impact on Survival in Head and Neck Cancer Patients. J. Clin. Med. 2018;7:501. doi: 10.3390/jcm7120501. PubMed DOI PMC

Li H., Wawrose J.S., Gooding W.E., Garraway L.A., Lui V.W.Y., Peyser N.D., Grandis J.R. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: A rational approach to preclinical model selection. Mol. Cancer Res. 2014;12:571–582. doi: 10.1158/1541-7786.MCR-13-0396. PubMed DOI PMC

Michalides R., Van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of Cyclin D1 Correlates with Recurrence in a Group of Forty-seven Operable Squamous Cell Carcinomas of the Head and Neck. Cancer Res. 1995;55:975–978. PubMed

Mineta H., Miura K., Takebayashi S., Ueda Y., Misawa K., Harada H., Wennerberg J., Dictor M. Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol. 2000;36:194–198. doi: 10.1016/S1368-8375(99)00078-0. PubMed DOI

Wong R.J., Keel S.B., Glynn R.J., Varvares M.A. Histological pattern of mandibular invasion by oral squamous cell carcinoma. Laryngoscope. 2000;110:65–72. doi: 10.1097/00005537-200001000-00013. PubMed DOI

Vielba R., Bilbao J., Ispizua A., Zabalza I., Alfaro J., Rezola R., Moreno E., Elorriaga J., Alonso I., Baroja A., et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope. 2003;113:167–172. doi: 10.1097/00005537-200301000-00031. PubMed DOI

Thomas G.R., Nadiminti H., Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int. J. Exp. Pathol. 2005;86:347–363. doi: 10.1111/j.0959-9673.2005.00447.x. PubMed DOI PMC

Rodrigo J.P., García-Carracedo D., García L.A., Menéndez S.T., Allonca E., González M.V., Fresno M.F., Suárez C., García-Pedrero J.M. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J. Pathol. 2009;217:516–523. doi: 10.1002/path.2462. PubMed DOI

Mellin H., Friesland S., Lewensohn R., Dalianis T., Munck-Wikland E. Human papilloma virus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int. J. Cancer. 2000;89:300–304. doi: 10.1002/1097-0215(20000520)89:3<300::AID-IJC14>3.0.CO;2-G. PubMed DOI

Strome S.E., Savva A., Brissett A.E., Gostout B.S., Lewis J., Clayton A.C., McGovern R., Weaver A.L., Persing D., Kasperbauer J.L. Squamous cell carcinoma of the tonsils: A molecular analysis of HPV associations. Clin. Cancer Res. 2002;8:1093–1100. PubMed

Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008;26:612–619. doi: 10.1200/JCO.2007.14.1713. PubMed DOI

Schwaederlé M., Daniels G.A., Piccioni D.E., Fanta P.T., Schwab R.B., Shimabukuro K.A., Parker B.A., Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015;6:3033–3042. doi: 10.18632/oncotarget.2848. PubMed DOI PMC

Vossen D., Verhagen C., Van der Heijden M., Essers P., Bartelink H., Verheij M., Wessels L., Van den Brekel M., Vens C. Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy. Cancers. 2019;11:445. doi: 10.3390/cancers11040445. PubMed DOI PMC

Britschgi A., Bill A., Brinkhaus H., Rothwell C., Clay I., Duss S., Rebhan M., Raman P., Guy C.T., Wetzel K., et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc. Natl. Acad. Sci. USA. 2013;110:E1026–E1034. doi: 10.1073/pnas.1217072110. PubMed DOI PMC

Janssen J.W.G., Imoto I., Inoue J., Shimada Y., Ueda M., Imamura M., Bartram C.R., Inazawa J. MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J. Hum. Genet. 2002;47:460–464. doi: 10.1007/s100380200065. PubMed DOI

Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905. doi: 10.1038/nature08822. PubMed DOI PMC

Faraji F., Schubert A.D., Kagohara L.T., Tan M., Xu Y., Zaidi M., Fortin J.-P., Fakhry C., Izumchenko E., Gaykalova D.A., et al. Molecular Determinants of Head and Neck Cancer. Humana Press; Totowa, NJ, USA: 2018. The Genome-Wide Molecular Landscape of HPV-Driven and HPV-Negative Head and Neck Squamous Cell Carcinoma; pp. 293–325. DOI

Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017–1021. doi: 10.1038/35082500. PubMed DOI

Choi Y.J., Li X., Hydbring P., Sanda T., Stefano J., Christie A.L., Signoretti S., Look A.T., Kung A.L., Von Boehmer H., et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22:438–451. doi: 10.1016/j.ccr.2012.09.015. PubMed DOI PMC

Otto T., Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer. 2017;17:93–115. doi: 10.1038/nrc.2016.138. PubMed DOI PMC

Sugahara K., Michikawa Y., Ishikawa K., Shoji Y., Iwakawa M., Shibahara T., Imai T. Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma. Int. J. Oncol. 2011:761–769. PubMed

Klein E.A., Assoian R.K. Transcriptional regulation of the cyclin D1 gene at a glance. J. Cell Sci. 2008;121:3853–3857. doi: 10.1242/jcs.039131. PubMed DOI PMC

Sauter E.R., Nesbit M., Litwin S., Klein-Szanto A.J., Cheffetz S., Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 1999;59:4876–4881. PubMed

Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699–2711. doi: 10.1101/gad.1256504. PubMed DOI

Ciemerych M.A., Kenney A.M., Sicinska E., Kalaszczynska I., Bronson R.T., Rowitch D.H., Gardner H., Sicinski P. Development of mice expressing a single D-type cyclin. Genes Dev. 2002;16:3277–3289. doi: 10.1101/gad.1023602. PubMed DOI PMC

Chen B., Pollard J.W. Cyclin D2 compensates for the loss of cyclin D1 in estrogen-induced mouse uterine epithelial cell proliferation. Mol. Endocrinol. 2003;17:1368–1381. doi: 10.1210/me.2003-0036. PubMed DOI

Lam E.W.-F., Glassford J., Banerji L., Thomas N.S.B., Sicinski P., Klaus G.G.B. Cyclin D3 Compensates for Loss of Cyclin D2 in Mouse B-lymphocytes Activated via the Antigen Receptor and CD40. J. Biol. Chem. 2000;275:3479–3484. doi: 10.1074/jbc.275.5.3479. PubMed DOI

Van Kempen P.M.W., Noorlag R., Braunius W.W., Moelans C.B., Rifi W., Savola S., Koole R., Grolman W., Van Es R.J.J., Willems S.M. Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2015;4:1525–1535. doi: 10.1002/cam4.499. PubMed DOI PMC

Clark E.S., Brown B., Whigham A.S., Kochaishvili A., Yarbrough W.G., Weaver A.M. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene. 2009;28:431–444. doi: 10.1038/onc.2008.389. PubMed DOI PMC

Togashi Y., Arao T., Kato H., Matsumoto K., Terashima M., Hayashi H., De Velasco M.A., Fujita Y., Kimura H., Yasuda T., et al. Frequent amplification of oraov1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ros production. Oncotarget. 2014;5:2962–2973. doi: 10.18632/oncotarget.1561. PubMed DOI PMC

Al Moustafa A.-E., Foulkes W.D., Wong A., Jallal H., Batist G., Yu Q., Herlyn M., Sicinski P., Alaoui-Jamali M.A. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004;23:5252–5256. doi: 10.1038/sj.onc.1207679. PubMed DOI

Holzinger D., Flechtenmacher C., Henfling N., Kaden I., Grabe N., Lahrmann B., Schmitt M., Hess J., Pawlita M., Bosch F.X. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int. J. Cancer. 2013;133:1389–1399. doi: 10.1002/ijc.28142. PubMed DOI

Plath M., Broglie M.A., Förbs D., Stoeckli S.J., Jochum W. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma. J. Otolaryngol. Head Neck Surg. 2018;47:1–9. doi: 10.1186/s40463-018-0298-3. PubMed DOI PMC

McLaughlin-Drubin M.E., Park D., Munger K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA. 2013;110:16175–16180. doi: 10.1073/pnas.1310432110. PubMed DOI PMC

Choi Y.J., Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890–1903. doi: 10.1038/onc.2013.137. PubMed DOI

Michel L., Ley J., Wildes T.M., Schaffer A., Robinson A., Chun S.-E., Lee W., Lewis J., Trinkaus K., Adkins D. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016;58:41–48. doi: 10.1016/j.oraloncology.2016.05.011. PubMed DOI PMC

Adkins D., Ley J., Neupane P., Worden F., Sacco A.G., Palka K., Grilley-Olson J.E., Maggiore R., Salama N.N., Trinkaus K., et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: A multicentre, multigroup, phase 2 trial. Lancet. Oncol. 2019;20:1295–1305. doi: 10.1016/S1470-2045(19)30405-X. PubMed DOI

Valach J., Fík Z., Strnad H., Chovanec M., Plzák J., Čada Z., Szabo P., Šáchová J., Hroudová M., Urbanová M., et al. Smooth muscle actin-expressing stromal fibroblasts in head and neck squamous cell carcinoma: Increased expression of galectin-1 and induction of poor prognosis factors. Int. J. Cancer. 2012;131:2499–2508. doi: 10.1002/ijc.27550. PubMed DOI

Szabó P., Kolář M., Dvořánková B., Lacina L., Štork J., Vlček Č., Strnad H., Tvrdek M., Smetana K. Mouse 3T3 fibroblasts under the influence of fibroblasts isolated from stroma of human basal cell carcinoma acquire properties of multipotent stem cells. Biol. Cell. 2011;103:233–248. doi: 10.1042/BC20100113. PubMed DOI

R Core Team R: A Language and Environment for Statistical Computing. [(accessed on 22 March 2020)]; Available online: http://www.r-project.org/

Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007. PubMed DOI PMC

Huber W., Carey V.J., Gentleman R., Anders S., Carlson M., Carvalho B.S., Bravo H.C., Davis S., Gatto L. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods. 2015;12:115–121. doi: 10.1038/nmeth.3252. PubMed DOI PMC

Leek J.T., Johnson W.E., Parker H.S., Fertig E.J., Jaffe A.E., Storey J.D., Zhang Y., Torres L.C. sva: Surrogate Variable Analysis. R package version 3.34.0. [(accessed on 22 March 2020)]; Available online: http://bioconductor.org/packages/release/bioc/html/sva.html.

Hahne F., Ivanek R. Visualizing Genomic Data Using Gviz and Bioconductor. In: Mathé E., Davis S., editors. Statistical Genomics. Volume 1418. Humana Press; New York, NY, USA: 2016. pp. 391–416. PubMed

Gu Z., Eils R., Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–2849. doi: 10.1093/bioinformatics/btw313. PubMed DOI

Liu J., Lichtenberg T., Hoadley K.A., Poisson L.M., Lazar A.J., Cherniack A.D., Kovatich A.J., Benz C.C., Levine D.A., Lee A.V., et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018;173:400–416. doi: 10.1016/j.cell.2018.02.052. PubMed DOI PMC

Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2:401–404. doi: 10.1158/2159-8290.CD-12-0095. PubMed DOI PMC

Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 2014;6:1–34. doi: 10.1126/scisignal.2004088. PubMed DOI PMC

Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1–21. doi: 10.1186/s13059-014-0550-8. PubMed DOI PMC

Therneau T. A Package for Survival Analysis in S. version 2.38. [(accessed on 22 March 2020)]; Available online: https://github.com/therneau/survival.

Kassambara A., Kosinski M., Biecek P., Scheipl F. Survminer: Drawing Survival Curves using “ggplot2.”. [(accessed on 22 March 2020)]; Available online: https://rpkgs.datanovia.com/survminer/index.html.

The Role of IL-6 in Cancer Cell Invasiveness and Metastasis-Overview and Therapeutic Opportunities